

## **Product datasheet for TL302357V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

# Phosphatidic acid phosphatase type 2B (PLPP3) Human shRNA Lentiviral Particle (Locus ID 8613)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

Product Name: Phosphatidic acid phosphatase type 2B (PLPP3) Human shRNA Lentiviral Particle (Locus ID

8613)

**Locus ID:** 8613

Synonyms: Dri42; LPP3; PAP2B; PPAP2B; VCIP

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: PPAP2B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 003713, NM 177414, NM 003713.1, NM 003713.2, NM 003713.3, NM 003713.4,

NM 177414.1, BC009196, BC009196.2, BM471786, BM719257

UniProt ID: <u>O14495</u>

**Summary:** The protein encoded by this gene is a member of the phosphatidic acid phosphatase (PAP)

family. PAPs convert phosphatidic acid to diacylglycerol, and function in de novo synthesis of glycerolipids as well as in receptor-activated signal transduction mediated by phospholipase D. This protein is a membrane glycoprotein localized at the cell plasma membrane. It has been shown to actively hydrolyze extracellular lysophosphatidic acid and short-chain

phosphatidic acid. The expression of this gene is found to be enhanced by epidermal growth

factor in Hela cells. [provided by RefSeq, Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.






### Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.


For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

## **Product images:**




GFP signal was observed under microscope at 48 hours after transduction of TL302357A virus into HEK293 cells. TL302357A virus was prepared using lenti-shRNA TL302357A and [TR30037] packaging kit.






GFP signal was observed under microscope at 48 hours after transduction of TL302357B virus into HEK293 cells. TL302357B virus was prepared using lenti-shRNA TL302357B and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL302357C] virus into HEK293 cells. [TL302357C] virus was prepared using lenti-shRNA [TL302357C] and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL302357D] virus into HEK293 cells. [TL302357D] virus was prepared using lenti-shRNA [TL302357D] and [TR30037] packaging kit.